Cargando…

Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report

RATIONALE: Anti-PD-1 antibody is the standard therapy for treatment-resistant gastric cancer, but only a limited number of patients respond. Additionally, cases of hyper-progressive disease (HPD) in which tumor growth accelerates after anti-PD-1 antibody administration have been reported; however, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Kyoko, Tsuchihashi, Kenji, Tsuji, Kunihiro, Kito, Yosuke, Tanoue, Kenro, Ohmura, Hirofumi, Ito, Mamoru, Isobe, Taichi, Ariyama, Hiroshi, Kusaba, Hitoshi, Akashi, Koichi, Baba, Eishi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133284/ https://www.ncbi.nlm.nih.gov/pubmed/34106609 http://dx.doi.org/10.1097/MD.0000000000025773

Ejemplares similares

Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report
por: Inadomi, Kyoko, et al.
Publicado: (2016)

PD‐1+ TIM‐3+ T cells in malignant ascites predict prognosis of gastrointestinal cancer
por: Nakano, Michitaka, et al.
Publicado: (2018)

Lingual alveolar soft part sarcoma responsive to pazopanib: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab
por: Tanoue, Kenro, et al.
Publicado: (2021)

Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report
por: Ueno, Shohei, et al.
Publicado: (2021)

Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy
por: Kusaba, Hitoshi, et al.
Publicado: (2016)

Regorafenib-induced retinal and gastrointestinal hemorrhage in a metastatic colorectal cancer patient with liver dysfunction: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

Inhibition of insulin‐like growth factor‐1 receptor enhances eribulin‐induced DNA damage in colorectal cancer
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2022)

Metastatic esophageal cancer presenting as shock by injury of vagus nerve mimicking baroreceptor reflex: A case report
por: Tsuchihashi, Kenji, et al.
Publicado: (2017)

Successful chemotherapeutic treatment for metastatic littoral cell angioma: A case report
por: Takayoshi, Kotoe, et al.
Publicado: (2018)

Thrombocytopenia Caused by Dexamethasone in a Patient with Colorectal Cancer
por: Taguchi, Ryosuke, et al.
Publicado: (2020)

Helper T cell-dominant tertiary lymphoid structures are associated with disease relapse of advanced colorectal cancer
por: Yamaguchi, Kyoko, et al.
Publicado: (2020)

Activation of central/effector memory T cells and T‐helper 1 polarization in malignant melanoma patients treated with anti‐programmed death‐1 antibody
por: Yamaguchi, Kyoko, et al.
Publicado: (2018)

Methylation of drug resistance‐related genes in chemotherapy‐sensitive Epstein–Barr virus‐associated gastric cancer
por: Ohmura, Hirofumi, et al.
Publicado: (2019)

Case Report: Resolution of remitting seronegative symmetrical synovitis with pitting edema during nivolumab therapy for gastric cancer
por: Ohmura, Hirofumi, et al.
Publicado: (2023)

OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
por: Ohmura, Hirofumi, et al.
Publicado: (2020)

Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis
por: Zhang, Yaxiong, et al.
Publicado: (2015)

Prognostic value of lactate dehydrogenase for melanoma patients receiving anti-PD-1/PD-L1 therapy: A meta-analysis
por: Xu, Jun, et al.
Publicado: (2021)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors
por: Li, Lingling, et al.
Publicado: (2021)

Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis
por: Zheng, Zheng, et al.
Publicado: (2020)

The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis
por: Wu, Lin-guang-jin, et al.
Publicado: (2021)

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials
por: Hao, Chunyan, et al.
Publicado: (2017)

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis
por: Wang, Qianqian, et al.
Publicado: (2017)

Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma: A meta-analysis of randomized controlled trials
por: Zhu, Peng, et al.
Publicado: (2021)

E-cadherin regulates proliferation of colorectal cancer stem cells through NANOG
por: Tamura, Shingo, et al.
Publicado: (2018)

Pneumonitis in cancer patients receiving anti-PD-1 and radiotherapies: Three case reports
por: Lu, Chieh-Sheng, et al.
Publicado: (2017)

Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma
por: Zhao, Yanjie, et al.
Publicado: (2020)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer
por: Zhou, Hui, et al.
Publicado: (2021)

A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers
por: Zhao, Jing-Wen, et al.
Publicado: (2023)

Primary leptomeningeal melanomatosis successfully treated with PD-1 inhibitor pembrolizumab: A case report
por: Misir Krpan, Ana, et al.
Publicado: (2020)

PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study
por: Özdirik, Burcin, et al.
Publicado: (2021)

Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials
por: Wei, Wei, et al.
Publicado: (2017)

Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report
por: Wang, Xia, et al.
Publicado: (2021)

Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report
por: Yoshihiro, Tomoyasu, et al.
Publicado: (2017)

Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
por: Luo, Yi, et al.
Publicado: (2021)

Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report
por: Wei, Tingting, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ibosqkah0gn75gac5d8eaieu99